MedTrace Logo

TAF Switch Study in Hepatitis B Monoinfection

NCT02957994 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2017-06-29

No results posted yet for this study

Summary

To evaluate various markers of renal function and bone density after the switch to Tenofovir alafenamide fumarate (TAF) in chronic hepatitis B patients who are currently treated with Tenofovir disoproxil fumarate (TDF) .

Conditions

Interventions

DRUG

Tenofovir alafenamide fumarate

Patients on TDF will be switched to TAF

Sponsors & Collaborators

  • Asian Pacific Liver Center at Coalition of Inclusive Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2017-06-21
Completion
2017-11-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02957994 on ClinicalTrials.gov